Inclusion Criteria:

- Patients must have histologically or cytologically confirmed adenocarcinoma of the
stomach or lower third of the oesophagusthat considered to be stage II (through the
submucosa) or higher, with no evidence of distant metastases, or locally advanced
inoperable disease, as evaluated by computed tomography, chest radiography,
ultrasonography, or laparoscopy.

- Patients must have evaluable or measurable disease, defined as at least one lesion
that can be accurately measured in at least one dimension (longest diameter to be
recorded) as >= 20 mm with conventional techniques or as >= 10 mm with spiral CT
scan.

- Age >= 18 years. Because no dosing or adverse event data are currently available on
the use of DCX in patients <18 years of age, children are excluded from this study.

- ECOG performance status <= 1 (see Appendix A).

- Patients must have normal organ and marrow function as defined below:

X leukocytes >= 3,000/mcL X absolute neutrophil count >= 1,500/mcL X
platelets >= 100,000/mcL X total bilirubin within normal
institutional limits X AST(SGOT)/ALT(SGPT) <= 2.5 X institutional upper limit of
normal X creatinine within normal institutional limits

- The effects of DCX on the developing human fetus at the recommended therapeutic dose
are unknown. For this reason, women of child-bearing potential and men must agree to
use adequate contraception (hormonal or barrier method of birth control; abstinence)
prior to study entry and for the duration of study participation. Should a woman
become pregnant or suspect she is pregnant while participating in this study, she
should inform her treating physician immediately.

- Ability to understand and the willingness to sign a written informed consent
document.

Exclusion Criteria:

- Patients who have had prior chemotherapy or radiotherapy.

- Patients may not be receiving any other investigational agents.

- Patients with stage I or IV cancer of the stomach or lower oesophagus.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to docetacel, cisplatin or capecitabine.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Pregnant women are excluded from this study because agents use in the study may cause
fetal harm.

- HIV-positive patients on combination antiretroviral therapy are ineligible because of
the potential for pharmacokinetic interactions with docetaxel. In addition, these
patients are at increased risk of lethal infections when treated with
marrow-suppressive therapy.